tradingkey.logo
tradingkey.logo
Search

Inotiv Inc

NOTV
Add to Watchlist
0.080USD
0.0000.00%
Close 06/30, 16:00ETQuotes delayed by 15 min
2.79MMarket Cap
LossP/E TTM

More Details of Inotiv Inc Company

Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.

Inotiv Inc Info

Ticker SymbolNOTV
Company nameInotiv Inc
IPO dateNov 25, 1997
CEOLeasure (Robert W)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endNov 25
Address2701 Kent Ave
CityWEST LAFAYETTE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code47906-1382
Phone13174634527
Websitehttps://www.inotiv.com/
Ticker SymbolNOTV
IPO dateNov 25, 1997
CEOLeasure (Robert W)

Company Executives of Inotiv Inc

Name
Name/Position
Position
Shareholding
Change
Dr. John E. Sagartz, Ph.D.
Dr. John E. Sagartz, Ph.D.
Chief Strategy Officer, Director
Chief Strategy Officer, Director
686.00K
-0.88%
Dr. Adrian Hardy, Ph.D.
Dr. Adrian Hardy, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
373.36K
-1.44%
Mr. John Gregory (Greg) Beattie
Mr. John Gregory (Greg) Beattie
Chief Operating Officer
Chief Operating Officer
180.99K
-3.19%
Dr. Nigel Brown, Ph.D.
Dr. Nigel Brown, Ph.D.
Independent Director
Independent Director
104.93K
+26.21%
Mr. Michael J. Harrington
Mr. Michael J. Harrington
Independent Director
Independent Director
76.89K
+35.76%
Ms. Andrea Castetter
Ms. Andrea Castetter
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
13.20K
-43.94%
Mr. R. Matthew Neff
Mr. R. Matthew Neff
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Robert W. Leasure, Jr.
Mr. Robert W. Leasure, Jr.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Beth A. Taylor
Ms. Beth A. Taylor
Chief Financial Officer, Senior Vice President - Finance
Chief Financial Officer, Senior Vice President - Finance
--
--
Mr. David Landman
Mr. David Landman
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. John E. Sagartz, Ph.D.
Dr. John E. Sagartz, Ph.D.
Chief Strategy Officer, Director
Chief Strategy Officer, Director
686.00K
-0.88%
Dr. Adrian Hardy, Ph.D.
Dr. Adrian Hardy, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
373.36K
-1.44%
Mr. John Gregory (Greg) Beattie
Mr. John Gregory (Greg) Beattie
Chief Operating Officer
Chief Operating Officer
180.99K
-3.19%
Dr. Nigel Brown, Ph.D.
Dr. Nigel Brown, Ph.D.
Independent Director
Independent Director
104.93K
+26.21%
Mr. Michael J. Harrington
Mr. Michael J. Harrington
Independent Director
Independent Director
76.89K
+35.76%
Ms. Andrea Castetter
Ms. Andrea Castetter
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
13.20K
-43.94%

FAQs

Who are the top five shareholders of Inotiv Inc?

The top five shareholders of Inotiv Inc are: Dr. John E. Sagartz, Ph.D.

How many institutions hold shares of Inotiv Inc (NOTV)?

As of 2026Q1, 168 institutions hold shares of Inotiv Inc, with a combined market value of approximately 8.11M, accounting for 23.58% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -4802422.00.
KeyAI